Дело T-***/**: *****************, Определение от **.**.2024 г.

Текст

... uraxpharm – dimethyl fumarate – Letter of the Commission drawing conclusions from a judgment of the Court of Justice – Measure not actionable – Inadmissibility – Hypothetical acts – Manifest inadmissibility)

In Case T‑226/23,

Neuraxpharm Pharmaceuticals SL, established in Barcelona (Spain), represented by K. Roox, T. De Meese, J. Stuyck, M. Van Nieuwenborgh and C. Dumont, lawyers,

applicant,

v

European Commission, represented by C. Valero and E. Mathieu, acting as Agents,

defendant,

THE GENERAL COURT (Fourth Chamber),

composed of R. da Silva Passos (Rapporteur), President, I. Reine and T. Pynnä, Judges,

Registrar: V. Di Bucci,

having regard to the written part of the procedure,

having regard to the order of 19 July 2023, Neuraxpharm Pharmaceuticals v Commission (T‑226/23 R, not published, EU:T:2023:409),

makes the following

Order

1. By its action under Article 263 TFEU, the applicant, Neuraxpharm Pharmaceuticals SL, seeks the annulment of the decision contained in the letter of the European Commission of 17 March 2023, with reference SANTE.DDG1.B.5/AL/mmc (2023) 2915367, concerning the interpretation and the consequences of the judgment of 16 March 2023, Commission and Others v Pharmaceutical Works Polpharma (C‑438/21 P to C‑440/21 P, EU:C:2023:213) (‘the contested measure’).

Background to the dispute

2. The applicant is a pharmaceutical company that develops and markets various medicinal products, including generic medicinal products.

3. On 9 August 1994, the Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) granted Fumapharm AG two marketing authorisations concerning two strengths of a medicinal product, Fumaderm, indicated for the treatment of ...